Tel：028-88610620
Email：pr@keymedbio.com/BD@keymedbio.com
● Keymed has entered into a global exclusive license agreement
with Astrazeneca for the development and commercialization
of CMG901, and will receive an upfront payment of $63m
on transaction, as well as aditional milestone payments of
up to $1.1bn and tiered royalties up to low double digits;
● The first subject has been dosed in Phase I clinical trial
of CM369 (CCR8), co-developed by Keymed & InnoCare
Company Profile Management Team Milestones Corporate Culture
R&D Center Pipeline Manufacturing Park Cooperation Expanded Access Policy
Corporate Governance Information Disclosure Financial Reports Stock Information IR Calendar Investor Presentations Email Alerts IR Contact
Latest News Media
Culture & Benefits
Contact Information Consultation Legal Statement Privacy
Tel：028-88610620
Email：pr@keymedbio.com/BD@keymedbio.com
蜀ICP备2022006281号